Page 1 | Search Results | Blood | American Society of Hematology

1-16 of 16

Sort by

Sort Order Select

Journal Articles

Donor Selection May Predict Improved Survival Outcomes after Allogeneic Hematopoietic Stem Cell Transplantation in Chronic Myelomonocytic Leukemia - Experience from a Tertiary Care Centre

RAM V Nampoothiri, MDDM MRCP (UK), Carol Chen, Zeyad Al-Shaibani, MD, Ivan Pasic, MDPhD, Arjun Law, MD, Wilson Lam, MD, Fotios Michelis, MD PhD, Dennis Dong Hwan Kim, MD PhD, Armin Gerbitz, MDPhD, Auro Viswabandya, MD, Jeffrey H. Lipton, MD PhD, Jonas Mattsson, MD, Rajat Kumar, MD, Santhosh Thyagu, MDDM

Blood (2020) 136 (Supplement 1): 23–24.

https://doi.org/10.1182/blood-2020-142982

Published: 2020

Journal Articles

Donor-Specific Isoagglutinin Clearance in ABO Mismatched Stem Cell Transplant Recipients: How Long Should It Normally Take?

John Chinawaeze Aneke, MBBS, FMCPath, Nayana Sondi, Santhosh Thyagu, MDDM, Christine M. Cserti-Gazdewich, BSc, MD FRCPC, Jacob Pendergrast, MDFRCPC

Blood (2018) 132 (Supplement 1): 1260.

https://doi.org/10.1182/blood-2018-99-115075

Published: 2018

Journal Articles

Combination of ATG and Post-Transplant Cyclophosphamide for Gvhd Prophylaxis in Matched Unrelated Donor Peripheral Blood Stem Cell Transplants for High-Risk Hematological Malignancies- a Single Centre Experience

Shruti Prem Sudha, MD DM, Eshetu G Atenafu, M.Sc., P.Stat, Queralt Salas Gay, MD, Zoe Evans, Zeyad Al-Shaibani, MD, David Loach, MD, Arjun Law, MDDM, Wilson Lam, MD, Santhosh Thyagu, MD DM, Fotios V. Michelis, MD PhD, Dennis Dong Hwan Kim, MD PhD, Jeffrey H. Lipton, MD PhD, Rajat Kumar, MD, Auro Viswabandya, MD DM

Blood (2018) 132 (Supplement 1): 4569.

https://doi.org/10.1182/blood-2018-99-111955

Published: 2018

Journal Articles

Safety and Efficacy of Haploidentical Peripheral Blood Stem Cell Transplantation for Myeloid Malignancies Using Post-Transplantation Cyclophosphamide and Anti-Thymocyte Globulin As Graft Versus Host Disease Prophylaxis

Queralt Salas Gay, MD, Arjun Law, MDDM, Wilson Lam, MD, Zeyad Al-Shaibani, MD, Fotios V. Michelis, MD PhD, Santhosh Thyagu, MDDM, Dennis Dong Hwan Kim, MD PhD, Jeff H. Lipton, MD PhD, Rajat Kumar, MD, Auro Viswabandya, MDDM

Blood (2018) 132 (Supplement 1): 2103.

https://doi.org/10.1182/blood-2018-99-119417

Published: 2018

Journal Articles

High Incidence but Very Low Mortality of Epstein Barr Virus Related Post-Transplantation Lymphoproliferative Disorder after T-Cell Replete Haploidentical Peripheral Blood Stem Cell Transplantation

Queralt Salas Gay, MD, Zeyad Al-Shaibani, MD, Wilson Lam, MD, Fotios V. Michelis, MD PhD, Santhosh Thyagu, MDDM, Dennis Dong Hwan Kim, MD PhD, Jeff H. Lipton, MD PhD, Rajat Kumar, MD, Auro Viswabandya, MDDM, Arjun Law, MDDM

Blood (2018) 132 (Supplement 1): 2104.

https://doi.org/10.1182/blood-2018-99-119162

Published: 2018

Journal Articles

Comparison of the Impact of Pre-Transplant Co-Morbidity Scores on Allogeneic Hematopoietic Stem Cell Transplant Outcomes

Mohammed A. Marei, Eshetu G Atenafu, MSc, P.Stat, Arjun Law, MD DM, Wilson Lam, MD, Rajat Kumar, MD, Santhosh Thyagu, MD DM, Auro Viswabandya, MD DM, Dennis Dong Hwan Kim, MD, Jeff H. Lipton, MD PhD, Hans A. Messner, MD PhD, Fotios V. Michelis, MD PhD

Blood (2018) 132 (Supplement 1): 4670.

https://doi.org/10.1182/blood-2018-99-113884

Published: 2018

Journal Articles

Comprehensive Analysis of Systemic Immunosuppression (SIS) Duration after Allogeneic Hematopoietic Stem Cell Transplant: Risk Score Model Provides Stratification of Patients According to Probability of SIS Discontinuation

Maria Rhida Bautista, MD FRACP, FRCPA, Arjun Law, MD DM, Wilson Lam, MD, Fotios V. Michelis, MD PhD, Santhosh Thyagu, MD DM, Auro Viswabandya, MD DM, Rajat Kumar, MD, Jeff H. Lipton, MD PhD, Hans A. Messner, MD PhD, Dennis Dong Hwan Kim, MD PhD

Blood (2018) 132 (Supplement 1): 3403.

https://doi.org/10.1182/blood-2018-99-119472

Published: 2018

Journal Articles

High Post-Transplant Ferritin Level Associates with Adverse Survival and Higher Mortality Rate following Allogeneic Hematopoietic Stem Cell Transplant, whereas Pre-Transplant Ferritin Level Does Not

Warren Fingrut, BSc, MD, Arjun Law, MD DM, Wilson Lam, MD, Fotios V. Michelis, MD PhD, Santhosh Thyagu, MD DM, Auro Viswabandya, MD DM, Rajat Kumar, MD, Jeffrey H. Lipton, MD PhD, Hans A. Messner, MD PhD, Dennis Dong Hwan Kim, MD

Blood (2018) 132 (Supplement 1): 3454.

https://doi.org/10.1182/blood-2018-99-113938

Published: 2018

Journal Articles

Pre-Transplant Pulmonary Function Test Parameters of FEF50% (Forced expiratory flow at 50% of forced vital capacity) and RV (residual volume) in Combination Can Predict the Risk for Development of Lung Gvhd after Allogeneic Transplantation

Wilson Lam, MD, Arjun Datt Law, MBBS, MD DM, Fotios V. Michelis, MD PhD, Santhosh Thyagu, MD, Auro Viswabandya, MDMDcine,DM Clinical Hematology, Jeffrey H. Lipton, MD PhD, Hans A. Messner, MD PhD, Theodore Marras, MD MSc, Shikha Mittoo, MD MHS, Dennis Kim, MD

Blood (2017) 130 (Supplement 1): 1973.

https://doi.org/10.1182/blood.V130.Suppl_1.1973.1973

Published: 2017

Journal Articles

Efficacy of Cidofovir in Treatment of BK Virus Induced Hemorrhagic Cystitis in Post Allogeneic Hematopoietic Cell Transplant Recipients

Eric Anthony Coomes, MD, Amanda Jacques, BScPharm, RPh, ACPR, Fotios V. Michelis, MD PhD, Dennis (Dong-Hwong) Kim, MD PhD, Santhosh Thyagu, MD, Auro Viswabandya, MDMDcine,DM Clinical Hematology, Jeff H. Lipton, MD PhD, Hans A. Messner, MD PhD, Uday Deotare, MD

Blood (2017) 130 (Supplement 1): 5479.

https://doi.org/10.1182/blood.V130.Suppl_1.5479.5479

Published: 2017

Journal Articles

Fludarabine/Busulfan Plus Low Dose TBI As Reduced Intensity Conditioning in Older Patients Undergoing Allogeneic Hematopoietic Cell Transplant for Myeloid Malignancies

Manar Mohamed Ibrahim Khalil, MD MBBS, MRCP, Hans A. Messner, MD PhD, Jeffrey H. Lipton, MD PhD, Dennis Dong Hwan Kim, MD PhD, Auro Viswabandya, MD DM, Santhosh Thyagu, MBBS, MD DM, Uday Deotare, MD DM, Fotios V. Michelis, MD PhD

Blood (2016) 128 (22): 4652.

https://doi.org/10.1182/blood.V128.22.4652.4652

Published: 2016

Journal Articles

Refined Hepatic Grading System Improves Risk Stratification of Long-Term Outcomes in the Patients Developing Chronic Gvhd

Saud Alhayli, MBBS, Elizabeth Shin, Wilson Lam, MD, Uday Deotare, MD DM, Fotios V. Michelis, MD PhD, Santhosh Thyagu, MBBS, MD DM, Auro Viswabandya, MD DM, Jeffrey H. Lipton, Hans A. Messner, PhD, Dennis Dong Hwan Kim, MD PhD

Blood (2016) 128 (22): 2235.

https://doi.org/10.1182/blood.V128.22.2235.2235

Published: 2016

Journal Articles

Effective Strategy to Prevent Acute Graft-Versus-Host Disease in Unrelated Donor Allogeneic Hematopoietic Cell Transplants By Using a Combination of Anti-Thymocyte Globulin (ATG), Post-Transplant Cyclophosphamide and Cyclosporine

Uday Deotare, MD DM, David Loach, MD, Fotios V. Michelis, MD PhD, Dennis D. Kim, MD PhD, Santhosh Thyagu, MBBS, MD DM, Jeffrey H. Lipton, MD PhD, Hans A. Messner, MD PhD, Auro Viswabandya, MD DM

Blood (2016) 128 (22): 5781.

https://doi.org/10.1182/blood.V128.22.5781.5781

Published: 2016

Journal Articles

Post Transplant Cyclophosphamide (PTCy) with Anti-Thymocyte Globulin (ATG) Effectively Reduces the Severe (Grade III-IV) Acute Graft-Versus-Host Disease (GVHD) When Compared to ATG Alone in Matched Unrelated Donor (MUD) Allogeneic Hematopoietic Cell Transplants

Uday Deotare, MD DM, David Loach, MD, Fotios V. Michelis, MD PhD, Dennis D. Kim, MD PhD, Santhosh Thyagu, MBBS, MD DM, Jeffrey H. Lipton, MD PhD, Hans A. Messner, MD PhD, Auro Viswabandya, MD DM

Blood (2016) 128 (22): 3430.

https://doi.org/10.1182/blood.V128.22.3430.3430

Published: 2016

Journal Articles

Comprehensive Analysis of Pre-Transplant Pulmonary Function Test Parameters Including FEV1, FVC, DLco, FEF50%/75%, Frc, RV and TLC As Prognostic Factors for Long-Term Outcomes after Allogeneic Transplantation

Wilson Lam, MD, Uday Deotare, MD DM, Jeffrey H. Lipton, MD PhD, Theodore Marras, MD MSc, Hans A. Messner, MD PhD, Fotios V. Michelis, MD PhD, Shikha Mittoo, MD MHS, Santhosh Thyagu, MBBS, MD DM, Auro Viswabandya, MD DM, Dennis Dong Hwan Kim, MD PhD

Blood (2016) 128 (22): 2253.

https://doi.org/10.1182/blood.V128.22.2253.2253

Published: 2016

Journal Articles

Outcome Following Second Allogeneic Hematopoietic Cell Transplantation: A Single Centre Experience

Hassan A. Aljasem, MBBS, MD, Hans A. Messner, MD PhD, Jeffrey H. Lipton, MD PhD, Dennis Dong Hwan Kim, MD PhD, Auro Viswabandya, MD DM, Santhosh Thyagu, MBBS, MD DM, Uday Deotare, MD DM, Fotios V. Michelis, MD PhD

Blood (2016) 128 (22): 5838.

https://doi.org/10.1182/blood.V128.22.5838.5838

Published: 2016

Update search

NARROW

Publications

Format

Article Type

Topics

Date

Availability

Donor Selection May Predict Improved Survival Outcomes after Allogeneic Hematopoietic Stem Cell Transplantation in Chronic Myelomonocytic Leukemia - Experience from a Tertiary Care Centre

Donor-Specific Isoagglutinin Clearance in ABO Mismatched Stem Cell Transplant Recipients: How Long Should It Normally Take?

Combination of ATG and Post-Transplant Cyclophosphamide for Gvhd Prophylaxis in Matched Unrelated Donor Peripheral Blood Stem Cell Transplants for High-Risk Hematological Malignancies- a Single Centre Experience

Safety and Efficacy of Haploidentical Peripheral Blood Stem Cell Transplantation for Myeloid Malignancies Using Post-Transplantation Cyclophosphamide and Anti-Thymocyte Globulin As Graft Versus Host Disease Prophylaxis

High Incidence but Very Low Mortality of Epstein Barr Virus Related Post-Transplantation Lymphoproliferative Disorder after T-Cell Replete Haploidentical Peripheral Blood Stem Cell Transplantation

Comparison of the Impact of Pre-Transplant Co-Morbidity Scores on Allogeneic Hematopoietic Stem Cell Transplant Outcomes

Comprehensive Analysis of Systemic Immunosuppression (SIS) Duration after Allogeneic Hematopoietic Stem Cell Transplant: Risk Score Model Provides Stratification of Patients According to Probability of SIS Discontinuation

High Post-Transplant Ferritin Level Associates with Adverse Survival and Higher Mortality Rate following Allogeneic Hematopoietic Stem Cell Transplant, whereas Pre-Transplant Ferritin Level Does Not

Pre-Transplant Pulmonary Function Test Parameters of FEF50% (Forced expiratory flow at 50% of forced vital capacity) and RV (residual volume) in Combination Can Predict the Risk for Development of Lung Gvhd after Allogeneic Transplantation

Efficacy of Cidofovir in Treatment of BK Virus Induced Hemorrhagic Cystitis in Post Allogeneic Hematopoietic Cell Transplant Recipients

Fludarabine/Busulfan Plus Low Dose TBI As Reduced Intensity Conditioning in Older Patients Undergoing Allogeneic Hematopoietic Cell Transplant for Myeloid Malignancies

Refined Hepatic Grading System Improves Risk Stratification of Long-Term Outcomes in the Patients Developing Chronic Gvhd

Effective Strategy to Prevent Acute Graft-Versus-Host Disease in Unrelated Donor Allogeneic Hematopoietic Cell Transplants By Using a Combination of Anti-Thymocyte Globulin (ATG), Post-Transplant Cyclophosphamide and Cyclosporine

Post Transplant Cyclophosphamide (PTCy) with Anti-Thymocyte Globulin (ATG) Effectively Reduces the Severe (Grade III-IV) Acute Graft-Versus-Host Disease (GVHD) When Compared to ATG Alone in Matched Unrelated Donor (MUD) Allogeneic Hematopoietic Cell Transplants

Comprehensive Analysis of Pre-Transplant Pulmonary Function Test Parameters Including FEV1, FVC, DLco, FEF50%/75%, Frc, RV and TLC As Prognostic Factors for Long-Term Outcomes after Allogeneic Transplantation

Outcome Following Second Allogeneic Hematopoietic Cell Transplantation: A Single Centre Experience

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only